Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(16 sites)
Austria
Medizinische Universität Wien, Vienna Belgium
Cliniques universitaires Saint-Luc, Brussels Czechia
Fakultni Thomayerova nemocnice, Prague France
Hôpital Européen Georges-Pompidou HEGP, Paris Centre Hospitalier Universitaire De Toulouse, Toulouse Greece
Laiko General Hospital Of Athens, Athens Latvia
Pauls Stradins Clinical University Hospital, Riga Lithuania
Vilnius University Hospital Santaros Klinikos, Vilnius Netherlands
Amsterdam UMC Stichting, Amsterdam Portugal
Hospital Curry Cabral - Centro Hospitalar de Lisboa Central - ULS Sao José, Lisbon Spain
Fundacio Puigvert, Barcelona Hospital Universitario 12 De Octubre, Madrid Clinica Universidad De Navarra, Pamplona Hospital Universitario Virgen De La Macarena, Seville University Hospital Virgen Del Rocio S.L., Seville Sweden
Karolinska University Hospital, Huddinge